The development of AXA-042 is based on vaccine adjuvant research from the laboratory of Professor David Jackson at the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. …
Australian company Axelia Oncology announces supply agreement for PBS-listed cancer medicine
February 17, 2025 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review - 12 September
September 12, 2025 - - Podcast -
Surely this is what the collapse of moral authority must look like
September 11, 2025 - - Latest News -
Artificial Intelligence can only accelerate Health Technology Assessments
September 11, 2025 - - Latest News -
Australian biotechs shine at Asia Pacific Cell and Gene Therapy Awards
September 11, 2025 - - Australian Biotech -
Trump administration announces new disclosure rules for medicine advertising
September 10, 2025 - - Latest News -
Chemist Warehouse partners with DoorDash to deliver health and beauty on demand
September 10, 2025 - - Latest News -
Cancer leaders unite to tackle equity and innovation at 2025 PCPA Summit
September 10, 2025 - - Latest News